

	Particulars	STANDALONE					
		Quarter Ended			Period Ended		Year Ended
		September-13	June-13	September-12	September-13	September-12	March-13
	(UnAudited)	(UnAudited)	(UnAudited)	(UnAudited)	(UnAudited)	(Audited)	
<b>PART- I</b>							
<b>1 (a) Net Sales / Income from Operations</b>							
Domestic	28,655	24,400	28,913	53,055	51,783	100,877	
Exports	20,002	18,445	11,840	38,447	23,039	48,952	
Total	48,657	42,845	40,753	91,502	74,822	149,829	
Less : Excise Duty	177	218	173	395	372	875	
Net Sales / Income from Operations	48,480	42,627	40,580	91,107	74,450	148,954	
<b>(b) Other Operating Income</b>	46	57	73	103	128	309	
<b>Total Income from Operations</b>	<b>48,526</b>	<b>42,684</b>	<b>40,653</b>	<b>91,210</b>	<b>74,578</b>	<b>149,263</b>	
<b>2 Expenses</b>							
(a) Decrease/(increase) in stock in trade and work in progress	(744)	(1,303)	1,949	(2,048)	1,807	2,134	
(b) Consumption of Raw Materials & Packing Materials	13,764	13,597	12,631	27,361	23,799	47,030	
(c) Purchase of traded goods	5,930	4,949	4,277	10,880	8,345	16,559	
(d) Employees' Cost	5,931	5,636	4,855	11,567	9,350	19,379	
(e) Research and Development Expense	3,121	2,070	1,603	5,190	2,991	7,363	
(f) Excise Duty	208	79	117	287	232	100	
(g) Other Expenditure	10,826	10,227	8,866	21,054	16,871	32,322	
<b>Total Expenses</b>	<b>39,036</b>	<b>35,255</b>	<b>34,298</b>	<b>74,291</b>	<b>63,395</b>	<b>124,887</b>	
<b>3 Profit from Operations before Other Income, Interest, Depreciation &amp; Exceptional Items</b>	<b>9,490</b>	<b>7,429</b>	<b>6,355</b>	<b>16,919</b>	<b>11,183</b>	<b>24,376</b>	
<b>4 Other Income</b>	<b>20</b>	<b>2</b>	<b>22</b>	<b>22</b>	<b>43</b>	<b>393</b>	
<b>5 Profit/(Loss) from Ordinary Activities before Interest, Depreciation, &amp; Exceptional Items</b>	<b>9,510</b>	<b>7,431</b>	<b>6,377</b>	<b>16,941</b>	<b>11,226</b>	<b>24,769</b>	
<b>6 Depreciation</b>	<b>985</b>	<b>953</b>	<b>882</b>	<b>1,938</b>	<b>1,747</b>	<b>3,496</b>	
<b>7 Interest (Net)</b>	<b>257</b>	<b>147</b>	<b>312</b>	<b>404</b>	<b>886</b>	<b>1,457</b>	
<b>8 Net Profit / (Loss) from Ordinary Activities before Tax</b>	<b>8,268</b>	<b>6,331</b>	<b>5,183</b>	<b>14,599</b>	<b>8,593</b>	<b>19,816</b>	
<b>9 Tax Expense</b>							
Less : Provision for Current Tax	1,739	1,327	1,042	3,066	1,729	3,975	
Less /Add : Provision for Deferred Tax Liability/(Assets)	146	57	(6)	203	(11)	96	
<b>10 Net Profit / (Loss) from Ordinary Activities after Tax</b>	<b>6,383</b>	<b>4,947</b>	<b>4,147</b>	<b>11,330</b>	<b>6,875</b>	<b>15,745</b>	
<b>11 Paid up Equity Share Capital</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	
( Face value of share Rs. 2/- )							
<b>12 Reserves excluding Revaluation Reserve</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>42,206</b>	
<b>13 Basic &amp; Diluted EPS (Not Annualised)</b>	<b>3.39</b>	<b>2.62</b>	<b>2.20</b>	<b>6.01</b>	<b>3.65</b>	<b>8.35</b>	
<b>PART- II</b>							
<b>A Particulars of Shareholding</b>							
<b>1 Public Shareholding</b>							
- Number of Shares	48777294	48777294	48777294	48777294	48777294	48777294	
- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87	
<b>2 Promoters and Promoter Group Shareholding</b>							
- Fully Non - Encumbered							
- Number of Shares	139738620	139738620	139738620	139738620	139738620	139738620	
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	
- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13	
<b>B INVESTOR COMPLAINTS</b>							
		<b>Quarter ended on 30th September, 2013</b>					
Pending at the beginning of the quarter		NIL					
Received during the quarter		2					
Disposed of during the quarter		2					
Remaining unresolved at the end of the quarter		NIL					



**ALEMBIC PHARMACEUTICALS LIMITED**  
 Regd. Office: Alembic Road, Vadodara 390 003  
**UNAUDITED FINANCIAL RESULTS**  
**FOR THE PERIOD ENDED 30th SEPTEMBER, 2013**

Rs. in Lacs

Particulars	CONSOLIDATED					
	Quarter Ended			Period Ended		Year Ended
	September-13	June-13	September-12	September-13	September-12	March-13
	(UnAudited)	(UnAudited)	(UnAudited)	(UnAudited)	(UnAudited)	(Audited)
<b>PART- I</b>						
<b>1 (a) Net Sales / Income from Operations</b>						
Domestic	28,655	24,400	28,913	53,055	51,783	100,877
Exports	20,112	18,477	11,840	38,590	25,776	51,723
Total	48,767	42,877	40,753	91,645	77,559	152,600
Less : Excise Duty	177	218	173	395	372	875
Net Sales / Income from Operations	48,590	42,659	40,580	91,250	77,187	151,725
<b>(b) Other Operating Income</b>	46	57	73	103	129	309
<b>Total Income from Operations</b>	48,636	42,716	40,653	91,353	77,316	152,034
<b>2 Expenses</b>						
(a) Decrease/(increase) in stock in trade and work in progress	(744)	(1,303)	1,949	(2,048)	1,807	2,134
(b) Consumption of Raw Materials & Packing Materials	13,764	13,597	12,631	27,361	23,799	47,030
(c) Purchase of traded goods	5,930	4,949	4,277	10,880	10,692	18,906
(d) Employees' Cost	5,931	5,636	4,855	11,567	9,350	19,379
(e) Research and Development Expense	3,382	2,241	1,603	5,622	2,991	7,363
(f) Excise Duty	208	79	117	287	232	100
(g) Other Expenditure	10,894	10,369	8,751	21,265	16,746	31,926
<b>Total Expenses</b>	39,365	35,568	34,183	74,934	65,617	126,838
<b>3 Profit from Operations before Other Income, Interest, Depreciation &amp; Exceptional Items</b>	9,271	7,148	6,470	16,419	11,699	25,196
<b>4 Other Income</b>	20	2	22	22	43	393
<b>5 Profit/(Loss) from Ordinary Activities before Interest, Depreciation, &amp; Exceptional Items</b>	9,291	7,150	6,492	16,441	11,742	25,589
<b>6 Depreciation</b>	985	953	882	1,938	1,748	3,497
<b>7 Interest (Net)</b>	257	147	312	404	886	1,457
<b>8 Net Profit / (Loss) from Ordinary Activities before Tax</b>	8,049	6,050	5,298	14,099	9,108	20,635
<b>9 Tax Expense</b>						
Less : Provision for Current Tax	1,739	1,329	1,055	3,068	1,786	4,014
Less/(Add) : Provision for Deferred Tax Liability /(Assets)	146	57	(6)	203	(11)	96
<b>10 Net Profit / (Loss) from Ordinary Activities after Tax</b>	6,164	4,664	4,249	10,828	7,333	16,525
<b>11 Paid up Equity Share Capital</b> ( Face value of share ₹ 2/- )	3,770	3,770	3,770	3,770	3,770	3,770
<b>12 Reserves excluding Revaluation Reserve</b>	-	-	-	-	-	46,524
<b>13 Basic &amp; Diluted EPS (Not Annualised)</b>	3.27	2.47	2.25	5.74	3.89	8.77
<b>PART- II</b>						
<b>A Particulars of Shareholding</b>						
<b>1 Public Shareholding</b>						
- Number of Shares	48777294	48777294	48777294	48777294	48777294	48777294
- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
<b>2 Promoters and Promoter Group Shareholding</b>						
- Fully Non - Encumbered						
- Number of Shares	139738620	139738620	139738620	139738620	139738620	139738620
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
<b>B INVESTOR COMPLAINTS</b>	Quarter ended on 30th September, 2013					
Pending at the beginning of the quarter	NIL					
Received during the quarter	2					
Disposed of during the quarter	2					
Remaining unresolved at the end of the quarter	NIL					

**Notes :**

- 1 The above results, have been duly reviewed by Statutory Auditor, recommended by the Audit Committee and approved by the Board of Directors. However, the unaudited results of the Subsidiary included in above have not been reviewed by Statutory Auditor. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the Company's website [www.alembic-india.com](http://www.alembic-india.com).
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

**For Alembic Pharmaceuticals Limited**

Place : Vadodara  
Date : 25th October 2013

**Chirayu Amin**  
**Chairman and Managing Director**

**Visit us at [www.alembic-india.com](http://www.alembic-india.com)**

**Alembic Pharmaceuticals Limited**

**Consolidated Statement of Assets and Liabilities**

**Rs. In Lacs**

Particulars	As at 30th Sept, 2013 (Unaudited)	As at 31st March, 2013 (Audited)
<b>A EQUITY AND LIABILITIES</b>		
<b>1 Shareholders' funds</b>		
(a) Share capital	3,770	3,770
(b) Reserves and surplus	58,181	46,524
<b>Sub-total - Shareholders' funds</b>	<b>61,951</b>	<b>50,294</b>
<b>2 Non-current liabilities</b>		
(a) Long-term borrowings	7,155	7,053
(b) Deferred tax liabilities (net)	1,703	1,390
(c) Other long-term liabilities	1,266	1,276
(d) Long-term provisions	712	606
<b>Sub-total - Non-current liabilities</b>	<b>10,836</b>	<b>10,325</b>
<b>3 Current liabilities</b>		
(a) Short-term borrowings	8,458	7,011
(b) Trade payables	28,674	23,996
(c) Other current liabilities	7,401	6,925
(d) Short-term provisions	1,173	6,231
<b>Sub-total - Current liabilities</b>	<b>45,706</b>	<b>44,163</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>118,493</b>	<b>104,782</b>
<b>B ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Fixed assets	40,525	37,648
(b) Non-current investments	336	330
(c) Long-term loans and advances	3,777	3,588
<b>Sub-total - Non-current assets</b>	<b>44,638</b>	<b>41,566</b>
<b>2 Current assets</b>		
(a) Inventories	28,498	26,683
(b) Trade receivables	28,605	23,287
(c) Cash and Bank Balance	878	1,611
(d) Short-term loans and advances	15,874	11,635
<b>Sub-total - Current assets</b>	<b>73,856</b>	<b>63,216</b>
<b>TOTAL - ASSETS</b>	<b>118,493</b>	<b>104,782</b>

**For Alembic Pharmaceuticals Limited**

Place : Vadodara  
Date : 25th October, 2013

**Chirayu Amin**  
**Chairman and Managing Director**